Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

PURPOSE: We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with advanced soft tissue or bone sarcoma with progressive disease. PATIENTS AND METHODS: Fifty-four patients were treated with o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Gounder, Mrinal M., Zer, Alona, Tap, William D., Salah, Samer, Dickson, Mark A., Gupta, Abha A., Keohan, Mary Louise, Loong, Herbert H., D’Angelo, Sandra P., Baker, Stephanie, Condy, Mercedes, Nyquist-Schultz, Kjirsten, Tanner, Lanier, Erinjeri, Joseph P., Jasmine, Francis H., Friedlander, Sharon, Carlson, Robert, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Rashal, Tami, Ellis, Joel, Kauffman, Michael, Shacham, Sharon, Schwartz, Gary K., Abdul Razak, Albiruni Ryan
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2016
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321073/
https://ncbi.nlm.nih.gov/pubmed/27458288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.6346
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky